Cargando…
Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 mainly causes damage to the lung, as well as other organs and systems such as the hearts, the immune system and so on. Although the pathogen...
Autores principales: | Li, Zhongwen, Niu, Shuaishuai, Guo, Baojie, Gao, Tingting, Wang, Lei, Wang, Yukai, Wang, Liu, Tan, Yuanqing, Wu, Jun, Hao, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645923/ https://www.ncbi.nlm.nih.gov/pubmed/33098357 http://dx.doi.org/10.1111/cpr.12939 |
Ejemplares similares
-
Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs
por: Wu, Jun, et al.
Publicado: (2020) -
A scalable culture system incorporating microcarrier for specialised mesenchymal stem cells from human embryonic stem cells
por: Gao, Tingting, et al.
Publicado: (2023) -
Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
por: Tan, Yuanqing, et al.
Publicado: (2020) -
First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
por: Wu, Jun, et al.
Publicado: (2020) -
Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis
por: Wu, Jun, et al.
Publicado: (2020)